Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis

Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induct...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Masanao, Yamamura, Takeshi, Maeda, Keiko, Sawada, Tsunaki, Mizutani, Yasuyuki, Ishikawa, Eri, Ohashi, Ayako, Kajikawa, Go, Furukawa, Kazuhiro, Ohno, Eizaburo, Honda, Takashi, Kawashima, Hiroki, Ishigami, Masatoshi, Fujishiro, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759717/
https://www.ncbi.nlm.nih.gov/pubmed/32727993
http://dx.doi.org/10.2169/internalmedicine.5302-20
Descripción
Sumario:Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20-year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.

Ejemplares similares